Abstract
Purpose
To evaluate the feasibility and efficacy of stereotactic body radiation therapy (SBRT) in the treatment of colorectal liver metastases.
Methods
Forty-two patients with inoperable colorectal liver metastases not amenable to radiofrequency ablation (RFA) were treated with SBRT for a total number of 52 lesions. All patients received a total dose of 75 Gy in 3 consecutive fractions. Mean size of the lesions was 3.5 cm (range 1.1–5.4). Toxicity was classified according to the Common Toxicity Criteria version 3.0.
Results
Median follow-up was 24 (range 4–47) months. The progression in field was observed in 5 lesions. Twenty-four months actuarial local control (LC) rate was 91 %. Median overall survival (OS) was 29.2 ± 3.7 months. Actuarial OS rate at 24 months was 65 %. Median progression-free survival was 12.0 ± 4.2 months; 24 months actuarial rate was 35 %. No patients experienced radiation-induced liver disease or grade ≥3 toxicity.
Conclusions
SBRT represents a feasible alternative for the treatment of colorectal liver metastases not amenable to surgery or other ablative treatments in selected patients, showing optimal LC and promising survival rate.
Similar content being viewed by others
References
Adam R, Wicherts DA, De Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835
Adam R, De Gramont A, Figueras R et al (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17:1225–1239
Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M (2012) Review and uses of stereotactic body radiation therapy for oligometastases Oncologist 17:1100–1107
Ambrosino G, Polistina F, Costantin G et al (2009) Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 29:3381–3384
Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo M, Brandi G (2006) Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 32:214–228
Bozzetti F, Cozzaglio L, Boracchi P, Marubini E, Doci R, Bignami P, Gennari L (1993) Comparing surgical resection of limited hepatic metastases from colorectal cancer to non-operative treatment. Eur J Surg Oncol 19:162–167
Chang D, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060–4069
Cirocchi R, Trastulli S, Boselli C et al (2012) Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev 6:CD006317
Clancy C, Burke J, Barry M, Kalady M, Coffey J (2014) A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol. doi:10.1245/s10434-014-3805-4
Corbin K, Hellman S, Weichselbaum R (2013) Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol 31:1384–1390
Dawson LA, Lawrence TS (2004) The role of radiotherapy in the treatment of liver metastases. Cancer 10:139–144
Dawson LA, Normolle D, Balter JM et al (2002) Analysis of radiation induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821
Demaria S, Formenti S (2012) Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2:153
Eisenhauer E, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Eriguchi T, Takeda A, Sanuki N et al (2013) Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys 85:1006–1011
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr
Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318
Gillams A, Lees W (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19:1206–1213
Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493
Herfarth KK, Debus J (2005) Stereotactic radiation therapy for liver metastases. Chirurg 76:564–569
Hoyer M, Roed H, Traberg HA et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830
Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P (2007) Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 67:793–798
Kavanagh BD, Bradley JD, Timmerman RD (2008) Stereotactic irradiation of tumors outside the central nervous system. In: Halperin EC, Perez CA, Brady LW (eds) Perez and Brady’s principles and practice of radiation oncology, 5th edn. Lippincott, Williams and Wilkins, Baltimore, pp 389–390
Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:1585–1591
Leonard G, Brenner B, Kemeny N (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23:2038–2048
Quan D, Gallinger S, Nhan C, On behalf of the Surgical Oncology Program at Cancer Care Ontario et al (2012) The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 151:860–870
Rule W, Timmerman R, Abdulrahman R et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18:1081–1087
Rusthoven KE, Kavanagh BD, Cardenes H et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572–1578
Saltz LB (2005) Metastatic colorectal cancer: is there one standard approach? Oncology (Williston Park) 19:1147–1154
Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77:1241–1246
Scorsetti M, Arcangeli S, Tozzi A et al (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastasis? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:336–342
Siperstein A, Berber E, Ballem N, Parikh R (2007) Survival after radiofrequency ablation of colorectal liver metastases. 10-year experience. Ann Surg 246:559–567
Timmerman R, Papiez L, McGarry R et al (2003) Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124:1946–1955
Tomlinson J, Jarnagin W, Dematteo R et al (2007) Actual 10-year survival after resection of 514 colorectal liver metastases defines cure. J Clin Oncol 25:4575–4580
van der Pool A, Mendez Romero A, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97:377–382
Yoon S, Tanabe K (1999) Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist 4:197–208
Conflict of interest
L. Cozzi acts as Scientific Advisor to Varian Medical Systems and is Head of Research and Technological Development to IOSI, Bellinzona. All other co-authors have no conflicts of interests. No other conflicts exist for all other authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scorsetti, M., Comito, T., Tozzi, A. et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 141, 543–553 (2015). https://doi.org/10.1007/s00432-014-1833-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-014-1833-x